Pharmafile Logo
Pharmafocus logo
Advanced Search

Q3

Showing 15 posts of 24 posts found.

valeant

Valeant’s tough year gets worse with Q3 loss of $1.22 billion

November 9, 2016
Research and Development Q3, Valeant, loss

It’s easy to say that Valeant hasn’t had a great year so far. Unfortunately for those concerned, the outlook for …

News

Lundbeck sales slide as generic competition bites

November 6, 2014
Sales and Marketing Ebixa, Lundbeck, Q3, Xenazine, generic, onfi, sabril

Lundbeck’s sales fell dramatically in the third quarter of 2014 as it struggles with expiring patents, although several of its …

News
Abbvie image

AbbVie financials beat expectations

October 31, 2014
Sales and Marketing AbbVie, Abbott, Creon, Humira, Iopinavir/ritonavir, Kaletra, Q3, Synthroid, levothyroxine, pancrelipase

AbbVie has announced higher-than-expected financial results for the third quarter of 2014, although it continues to rely heavily on blockbuster …

News
Merck image

Merck revenue falls

October 28, 2014
Manufacturing and Production, Sales and Marketing Frazier, Merck, Q3, Victrelis, hep C, sovaldi

Merck has posted a set of disappointing financials for the latest quarter as it cuts cost across its business to …

News
Celgene image

Celgene expands immunotherapy pipeline with Sutro

October 27, 2014
Research and Development, Sales and Marketing Celgene, PD-1 and PD-L1, Q3, oncology, sutro

Celgene has extended its collaboration with Sutro Biopharma and added a buyout option for the firm as the two companies …

News
Lilly image

Lacklustre sales hit Lilly again

October 24, 2014
Sales and Marketing Q3, cymbalta, humilin, lilly, sales, zyprexa

Lilly is enduring one of the bleakest financial years in its history as patent expiries continue to take chunks out …

News
Viiv image

GSK mulls $27 billion ViiV sell-off

October 23, 2014
Medical Communications, Sales and Marketing AIDS, Advair, GSK, HIV, Pfizer, Q3, Shionogi, Tivicay, ViiV

After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing …

News
Roche image

New cancer drugs escalate Roche earnings

October 16, 2014
Research and Development, Sales and Marketing Cancer, Herceptin (trastuzumab), Kadcyla, Perjeta, Q3, Roche, ado-trastuzumab emtansine, pertuzumab

Roche’s sales saw solid growth in the first nine months of the year, increased by the firm’s new cancer medicines. …

News
Astrazeneca image

More changes at the top as AstraZeneca profits slip

November 1, 2013
Sales and Marketing AstraZeneca, Crestor, Q3, profits

AstraZeneca’s third quarter revenues and profits fell below analysts’ expectations yesterday, but mitigated the news with the appointment of a …

News

Cancer drugs lift Pfizer in third quarter

October 30, 2013
Sales and Marketing Lipitor, Lyrica, Pfizer, Q3, Xalkori

Pfizer saw a drop in revenue for the third quarter but the future looks bright as new products begin to …

News
biogen idec image

Strong sales for Biogen Idec’s MS drug

October 29, 2013
Sales and Marketing Biogen IDEC, Q3, gilenya, tecfidera

Biogen Idec’s oral multiple sclerosis (MS) drug Tecfidera lived up to its blockbuster-in-waiting billing with third quarter sales that exceeded …

News
GSK image

Corruption probe hits GSK

October 24, 2013
Sales and Marketing China, GSK, Q3, corruption

The fallout from corruption investigations in China has hit GlaxoSmithKline, which announced third quarter sales in the country were down …

News
Novartis image

Novartis sees profit slip

October 23, 2013
Sales and Marketing Afinitor, Diovan, Novartis, Q3, gilenya

Novartis saw generic competition erode profit in the third quarter of the year, although sales across the group actually rose …

News
jj_2johnson_and_johnson

Johnson & Johnson posts strong Q3 results

October 16, 2013
Sales and Marketing J&J, JJ, Q3, Velcade, results

Johnson & Johnson has posted a strong set of financials for the third quarter as new products from its pharma …

News

Pfizer stumbles in third quarter

November 2, 2012
Research and Development, Sales and Marketing Ian Read, Lipitor, Pfizer, Prevnar, Q3

Pfizer has experienced a worse than expected third quarter, due to disappointing sales of paediatric vaccine Prevnar and a surprise …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025